|
| Status |
Public on Sep 13, 2011 |
| Title |
Triple-negative breast cancer_001 |
| Sample type |
RNA |
| |
|
| Source name |
primary breast cancer tissue
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: triple-negative breast cancer
lymph node status (0: negative, 1: positive): 0
grade (12: G1 or G2, 3: G3): 3
tumor size (1: up to 1 cm, 2: >1cm): 2
event-free interval (months): 93
event (1: yes, 0: no): 0
cohort: HH
biopsy type (1: surgical, 2: core needle): 1
chemotherapy treatment (yes/no): NO
neoadjuvant chemotherapy (yes/no): NO
|
| Treatment protocol |
Samples were snap frozen and stored at -80°C.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Qiagen RNeasy kit according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Starting from 5 µg total RNA, labeled cRNA was prepared using the Roche Microarray cDNA Synthesis, Microarray RNA Target Synthesis (T7) and Microarray Target Purification Kits according to the manufacturer's instructions.
|
| |
|
| Hybridization protocol |
Following fragmentation, 15 µg of cRNA were hybridized for 16 hr at 45°C on the GeneChip HG-U133A array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.
|
| Scan protocol |
GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.
|
| Description |
TNBC_001
Gene expression data from primary breast tumors.
|
| Data processing |
The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 500.
|
| |
|
| Submission date |
Aug 18, 2011 |
| Last update date |
Sep 23, 2011 |
| Contact name |
Thomas Karn |
| E-mail(s) |
t.karn@em.uni-frankfurt.de
|
| Organization name |
J.W.Goethe-University
|
| Street address |
Theodor-Stern-Kai 7
|
| City |
Frankfurt |
| ZIP/Postal code |
60590 |
| Country |
Germany |
| |
|
| Platform ID |
GPL96 |
| Series (1) |
| GSE31519 |
A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
|
